A
AEON
Aeon Biopharma
0.2940
+0.0300+11.36%After Hours: 0.2861 -0.0079 -2.69%16:17 10/29 EDT
OPEN/PREV CLOSE0.2640/0.2640
TODAY RANGE0.2640-0.3100
VOL1.32M
MARKET CAP17.37M
52 WEEK RANGE0.1772-1.450
AVG VOL (3M)7.54M
% TURNOVER2.24%
TURNOVER--
P/E (TTM)-0.0820
% RANGE17.42%
EPS(TTM)-3.5840
P/E(FORWARD)-0.3920
P/B-0.5035
BVPS-0.5839
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP9.69M
SHARES OUTSTANDING59.08M
NEXT EARNINGS--
FREE FLOAT32.97M
LOT SIZE1
EX-DATE02/26/2025
News
Press Releases
Financial Reports
Profile
Benzinga·10/02 21:05
12 Health Care Stocks Moving In Friday's After-Market Session
NASDAQ·10/02 13:06
AEON Biopharma Consensus Price Target Raised by 16.39% to $1.81
Benzinga·10/01 18:10
Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday
Dow Jones·10/01 16:19
AEON Biopharma Is Maintained at Buy by Lake Street
Benzinga·10/01 16:10
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2
TipRanks·10/01 12:46
Aeon Biopharma price target raised to $2 from $1 at Lake Street
NASDAQ·09/30 18:49
Biotech Stocks Surge - NIVF +124%, CNTB +124%, SGMT +9%, VBIO +12%, AEON
Benzinga·09/30 17:06
12 Health Care Stocks Moving In Wednesday's Intraday Session
TipRanks·09/30 13:16
Lake Street Remains a Buy on AEON Biopharma (AEON)
NASDAQ·09/30 12:37
AEON Gains FDA Feedback On ABP-450 Biosimilar Pathway
TipRanks·09/30 12:34
AEON Biopharma advances ABP-450 biosimilar development strategy
NASDAQ·09/30 12:30
AEON Clarifies ABP-450 Biosimilar Development Plan
TipRanks·09/30 12:15
Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450
Same Industry
Name/Symbol
Change%
Price